Shin Nippon Biomedical Laboratories, Ltd.
2395.T · JPX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.11 | -0.67 | -1.05 | 0.17 |
| FCF Yield | 0.00% | 0.00% | 0.00% | 0.00% |
| EV / EBITDA | 52.08 | 74.11 | 32.08 | 30.73 |
| Quality | ||||
| ROIC | 0.40% | -0.36% | 1.24% | 1.84% |
| Gross Margin | 43.53% | 47.38% | 48.02% | 53.05% |
| Cash Conversion Ratio | – | – | – | – |
| Growth | ||||
| Revenue 3-Year CAGR | 9.20% | 7.49% | 8.91% | 13.18% |
| Free Cash Flow Growth | 0.00% | 0.00% | 0.00% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | 14.26 | 22.02 | 8.78 | 7.93 |
| Interest Coverage | 5.69 | -5.90 | 20.00 | 33.46 |
| Efficiency | ||||
| Inventory Turnover | 0.37 | 0.28 | 0.42 | 0.32 |
| Cash Conversion Cycle | 299.45 | 386.08 | 264.39 | 327.15 |